Examkin

Soru

Zorluk: ZorInfectious Diseases

A 71-year-old man is evaluated in the intensive care unit regarding his antimicrobial regimen. He was admitted 12 days ago for acute respiratory distress syndrome secondary to a severe viral pneumonitis and required endotracheal intubation. Five days ago, his clinical status deteriorated with the development of a fever up to 39.4°C (102.9°F), worsening hypoxia, and thick, purulent endotracheal secretions. A chest radiograph at that time demonstrated a new dense consolidation in the left lower lobe. Empiric intravenous therapy with piperacillin-tazobactam, tobramycin, and vancomycin was initiated.

Today, the patient is clinically improving; he is afebrile (37.1°C [98.8°F]), and his ventilator settings have been significantly weaned. The quantitative bronchoalveolar lavage culture obtained five days ago exhibits heavy growth (10510^5 CFU/mL) of *Pseudomonas aeruginosa*. Antimicrobial susceptibility testing indicates the organism is susceptible to piperacillin-tazobactam, cefepime, and ciprofloxacin, but resistant to tobramycin. No other organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA), have been isolated. Blood cultures show no growth.

Which of the following is the most appropriate next step in this patient's pharmacotherapy?

  1. Discontinue tobramycin and vancomycin, and continue piperacillin-tazobactam monotherapyCevap
  2. B
    Discontinue vancomycin and substitute intravenous ciprofloxacin for tobramycin, while continuing piperacillin-tazobactam
  3. C
    Discontinue tobramycin, and continue piperacillin-tazobactam and vancomycin
  4. D
    Discontinue piperacillin-tazobactam, tobramycin, and vancomycin, and initiate meropenem monotherapy
  5. E
    Continue the current regimen of piperacillin-tazobactam, tobramycin, and vancomycin without modifications

Cevap

Discontinue tobramycin and vancomycin, and continue piperacillin-tazobactam monotherapy.
The correct approach for this patient is to discontinue both tobramycin and vancomycin, continuing only piperacillin-tazobactam. The fundamental principle of antimicrobial stewardship in ventilator-associated pneumonia (VAP) is to initiate broad empiric therapy but de-escalate as soon as culture and susceptibility data are available. Because quantitative cultures did not yield MRSA, vancomycin must be stopped to reduce nephrotoxicity risk. Although empiric dual coverage for *Pseudomonas aeruginosa* (e.g., a beta-lactam plus an aminoglycoside) is appropriate to ensure initial activity against potentially resistant isolates, definitive therapy should be narrowed to a single active beta-lactam once susceptibilities are confirmed, provided the patient is not in septic shock. Piperacillin-tazobactam alone is fully active against this isolate and is sufficient for definitive cure.

Adım Adım Çözüm

1
Evaluate the need for continued methicillin-resistant Staphylococcus aureus (MRSA) coverage.
The respiratory cultures did not grow MRSA.
Empiric MRSA coverage (vancomycin) should be discontinued if cultures are negative, in accordance with antimicrobial stewardship principles.
2
Assess the requirement for dual anti-pseudomonal therapy.
The patient's isolate is susceptible to piperacillin-tazobactam, and he is clinically improving.
Dual therapy is recommended for empiric coverage of suspected Pseudomonas infection to increase the likelihood of administering at least one active agent. Once susceptibilities are confirmed, definitive therapy with a single active beta-lactam is indicated.
3
Select the appropriate definitive regimen.
Discontinue tobramycin and vancomycin, retaining piperacillin-tazobactam.
Piperacillin-tazobactam provides adequate targeted monotherapy against this susceptible isolate while minimizing toxicity and resistance pressure.

Anahtar Kavram

In the management of ventilator-associated pneumonia, once pathogen susceptibilities are identified and the patient shows clinical improvement, empiric broad-spectrum therapy should be de-escalated. This includes stopping MRSA coverage if no MRSA is isolated and narrowing dual anti-pseudomonal therapy to a single active beta-lactam agent.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru